Traduction de «use and risk » (Néerlandais → Français) :

TERMINOLOGIE

controle van zwangerschap met verhoogd risico [high-risk]
Surveillance d'une grossesse à haut risque

TRADUCTIONS EN CONTEXTE

Lip GYH, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.
predict warfarin-associated hemorrhage. The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.

narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September
narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September

The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.
The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing

Oral contraceptive use as a risk factor for premenopausal breast cancer:
Oral contraceptive use as a risk factor for premenopausal

(Khader 2003) Khader YS, Rice J, Lefante J, Abueita O. Oral contraceptive use and the risk of myocardial infarction: a meta-analysis.
(Khader 2003) Khader YS, Rice J, Lefante J, Abueita O. Oral contraceptive use and the risk of myocardial infarction: a metaanalysis. Contraception 2003; 68:11-7

Dit zou vooral het geval zijn bij hogere doses en langere behandelingsduur [FDA Drug safety communication: possible increased risk of fractures of the hip, wrist and spine with the use of proton pump inhibitors.
Ce serait surtout le cas lors de l’utilisation de doses élevées et de traitement de longue durée. [FDA Drug safety communication: possible increased risk of fractures of the hip, wrist and spine with the use of proton pump inhibitors.

Does insertion and use of an intrauterine device increase the risk of pelvic
Does insertion and use of an intrauterine device increase the risk of

(Margolis 2007) Margolis KL, Adami HO, Luo J et al. A prospective study of oral contraceptive use and risk of myocardial infarction among
(Margolis 2007) Margolis KL, Adami HO, Luo J et al. A prospective study of oral contraceptive use and risk of myocardial

(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral contraceptives
(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral